

Prof. ÜMİT YAŞAR

Personal Information

Office Phone: [+90 312 305 1086](tel:+903123051086)

Office Phone: [+90 312 305 1087](tel:+903123051087)

Fax Phone: [+90 312 310 5312](tel:+903123105312)

Email: uyasar@hacettepe.edu.tr

Address: Hacettepe Üniversitesi, Tıp Fakültesi, Tıbbi Farmakoloji Anabilim Dalı, 06100 Sıhhiye Ankara

Education Information

Doctorate, Karolinska Institutet (Karolinska Institute), Department Of Clinical Pharmacology, Sweden 1997 - 2002

Under Graduate, Hacettepe Üniversitesi, Tıp Fakültesi, Turkey 1987 - 1994

Foreign Languages

English, B2 Upper Intermediate

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Pharmacology and Clinical Pharmacology

Academic Titles / Tasks

Professor, Hacettepe Üniversitesi, Tıp Fakültesi (ingilizce), Dahili Tıp Bilimleri Bölümü, 2010 - Continues

Associate Professor, Hacettepe Üniversitesi, Tıp Fakültesi (ingilizce), Dahili Tıp Bilimleri Bölümü, 2005 - 2010

Assistant Professor, Hacettepe Üniversitesi, Tıp Fakültesi (ingilizce), Dahili Tıp Bilimleri Bölümü, 2004 - 2005

Lecturer, Hacettepe Üniversitesi, Tıp Fakültesi (ingilizce), Dahili Tıp Bilimleri Bölümü, 2003 - 2004

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **Increased risk for cerebral ischemic stroke in diabetes: genetically polymorphic CYP mediated production of neuroprotective EETs and sulfonylurea metabolism in relation with K-ATP channels**
YAŞAR Ü., BABAĞLU M. Ö.
ACTA PHARMACOLOGICA SINICA, vol.40, no.4, pp.569-570, 2019 (Journal Indexed in SCI)
- II. **Two-sided action of Danshen on cytoprotective endogenous substances, epoxyeicosatrienoic acids**
YAŞAR Ü.
CHEMICO-BIOLOGICAL INTERACTIONS, vol.291, pp.152, 2018 (Journal Indexed in SCI)
- III. **Extracorporeal circulation systems in coronary artery bypass surgery can affect pharmacokinetics of drugs: may altered CYP-mediated liver function be a possible reason?**
YAŞAR Ü., BABAĞLU M. Ö.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.74, no.8, pp.1095, 2018 (Journal Indexed in SCI)
- IV. **Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2?**
YAŞAR Ü.

DRUG DESIGN DEVELOPMENT AND THERAPY, vol.12, pp.2169-2170, 2018 (Journal Indexed in SCI)

- V. **The role of pharmacogenetics of cytochrome P450s in phenytoin-induced DRESS syndrome**
YAŞAR Ü.
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, vol.43, no.2, pp.220-221, 2018 (Journal Indexed in SCI)
- VI. **Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behcet's Disease**
Goktas M. T. , KARACA R. O. , KALKISIM S., Cevik L., KILIC L., AKDOĞAN A., BABAOĞLU M. Ö. , Bozkurt A., Bertilsson L., YAŞAR Ü.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.121, no.4, pp.266-271, 2017 (Journal Indexed in SCI)
- VII. **Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication**
Karaca R. O. , Kalkisim S., Altinbas A., Kilincalp S., Yuksel I., Goktas M. T. , YAŞAR Ü., Bozkurt A., BABAOĞLU M. Ö.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.120, no.2, pp.199-206, 2017 (Journal Indexed in SCI)
- VIII. **EFFECTS OF GENETIC POLYMORPHISMS OF MULTI DRUG RESISTANCE PROTEIN (MDR1) ON LANSOPRAZOLE METABOLISM IN PEDIATRIC PATIENTS**
Karaca R. O. , Kalkisim S., GÜMÜŞ E., Goktas M. T. , YÜCE A., YAŞAR Ü., BOZKURT A., BABAOĞLU M. Ö.
DRUG METABOLISM AND PHARMACOKINETICS, vol.32, no.1, 2017 (Journal Indexed in SCI)
- IX. **mu-Opioid Receptor Gene (OPRM1) Polymorphisms A118G and C17T in Alcohol Dependence: A Turkish Sample**
GÜREL Ş. C. , AYHAN Y., Karaaslan C., Akel H., KARACA R. O. , BABAOĞLU M. Ö. , YAŞAR Ü., Bozkurt A., Dilbaz N., ULUĞ B. D. , et al.
TURK PSIKIYATRI DERGISI, vol.27, no.2, pp.75-83, 2016 (Journal Indexed in SSCI)
- X. **Relationship between genetic polymorphisms of drug efflux transporter MDR1 (ABCB1) and response to losartan in hypertension patients.**
GÖKTAŞ M., PEPEDIL F., KARACA Ö., KALKIŞIM S. N. , Cevik L., GUMUS E., GUVEN G., BABAOĞLU M. Ö. , BOZKURT A., YASAR U.
European review for medical and pharmacological sciences, vol.20, pp.2460-7, 2016 (Journal Indexed in SCI Expanded)
- XI. **Lower CYP2C9 activity in Turkish patients with Beh double dagger et's disease compared to healthy subjects: a down-regulation due to inflammation?**
Goktas M. T. , Hatta F., KARACA O., KALKISIM S., KILIC L., AKDOĞAN A., BABAOĞLU M. Ö. , Bozkurt A., Hellden A., Bertilsson L., et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.71, no.10, pp.1223-1228, 2015 (Journal Indexed in SCI)
- XII. **Association between ADH1C and ALDH2 polymorphisms and alcoholism in a Turkish sample**
AYHAN Y., GÜREL Ş. C. , KARACA O., ZOTO T., HAYRAN M., BABAOĞLU M., YAŞAR Ü., Bozkurt A., DILBAZ N., ULUĞ B. D. , et al.
NORDIC JOURNAL OF PSYCHIATRY, vol.69, no.3, pp.233-239, 2015 (Journal Indexed in SCI)
- XIII. **Improved Anti-Emetic Efficacy of 5-HT3 Receptor Antagonists in Cancer Patients with Genetic Polymorphisms of ABCB1 (MDR1) Drug Transporter**
Zoto T., KILIÇKAP S., YAŞAR Ü., ÇELİK İ., BOZKURT A., BABAOĞLU M. Ö.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.116, no.4, pp.354-360, 2015 (Journal Indexed in SCI)
- XIV. **Translating Biotechnology to Knowledge-Based Innovation, Peace, and Development? Deploy a Science Peace Corps-An Open Letter to World Leaders**
Hekim N., Coskun Y., Sinav A., Abou-Zeid A. H. , Agirbasli M., Akintola S. O. , Aynacioglu S., BAYRAM M., Bragazzi N. L. , Dandara C., et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, vol.18, no.7, pp.415-420, 2014 (Journal Indexed in SCI)
- XV. **Bernard Lerer: Recipient of the 2014 Inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics)**
Ozdemir V., Endrenyi L., Aynacioglu S., Bragazzi N. L. , Dandara C., Dove E. S. , Ferguson L. R. , Geraci C. J. , Hafen E., Kesim B. E. , et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY, vol.18, no.4, pp.211-221, 2014 (Journal Indexed in SCI)
- XVI. **Ocular Pharmacokinetics, Safety and Efficacy of Intracameral Moxifloxacin 0.5% Solution in a Rabbit**

Model

Akova Y., ASENSA L., Goktas M., BOZKURT A., YAŞAR Ü., Karabay G., Demiralay E.

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol.54, no.15, 2013 (Journal Indexed in SCI)

- XVII. **Evidence for regulation of UDP-glucuronosyltransferase (UGT) 1A1 protein expression and activity via DNA methylation in healthy human livers**
Yasar U., Greenblatt D. J., Guillemette C., Court M. H.
JOURNAL OF PHARMACY AND PHARMACOLOGY, vol.65, no.6, pp.874-883, 2013 (Journal Indexed in SCI)
- XVIII. **Ocular Pharmacokinetics, Safety and Efficacy of Intracameral Moxifloxacin 0.5% Solution in a Rabbit Model**
ASENSA L., Akova Y. A., GÖKTAŞ M. T., BOZKURT A., YAŞAR Ü., Karabay G., Demiralay E.
CURRENT EYE RESEARCH, vol.38, no.4, pp.472-479, 2013 (Journal Indexed in SCI)
- XIX. **The Therapeutic Effects of Melatonin and Nimodipine in Rats after Cerebral Cortical Injury**
İSMAİLOĞLU Ö., ATILLA P., Palaoglu S., Cakar N., YAŞAR Ü., Kilinc K., Kaptanoglu E.
TURKISH NEUROSURGERY, vol.22, no.6, pp.740-746, 2012 (Journal Indexed in SCI)
- XX. **Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9*5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects**
Allabi A. C., Horsmans Y., Alvarez J., Bigot A., Verbeeck R. K., YAŞAR Ü., Gala J.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, vol.37, no.2, pp.125-132, 2012 (Journal Indexed in SCI)
- XXI. **Evaluation of lansoprazole as a probe for assessing cytochrome P450 2C19 activity and genotype-phenotype correlation in childhood**
GÜMÜŞ E., Karaca O., BABAĞLU M. Ö., BAYSOY G., Balamtekin N., DEMİR H., USLU KIZILKAN N., BOZKURT A., YÜCE A., YAŞAR Ü.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.68, no.5, pp.629-636, 2012 (Journal Indexed in SCI)
- XXII. **Aqueous humour penetration of moxifloxacin and gatifloxacin eye drops in different dosing regimens before phacoemulsification surgery**
Gungor S. G., Akova Y. A., Bozkurt A., YAŞAR Ü., BABAĞLU M. Ö., Cetinkaya A., Colak M.
BRITISH JOURNAL OF OPHTHALMOLOGY, vol.95, no.9, pp.1272-1275, 2011 (Journal Indexed in SCI)
- XXIII. **Effect of Atorvastatin on CYP2C9 Metabolic Activity as Measured by the Formation Rate of Losartan Metabolite in Hypercholesterolaemic Patients**
YAŞAR Ü., SAİN GÜVEN G., Yardimci Y., KILIÇARSLAN A., BABAĞLU M. Ö., BOZKURT A.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.109, no.2, pp.73-77, 2011 (Journal Indexed in SCI)
- XXIV. **CYP1A2*1F Polymorphism Decreases Clinical Response to Clozapine in Patients with Schizophrenia**
Balibey H., Basoglu C., Lundgren S., BABAĞLU M. Ö., YAŞAR Ü., Herken H., Rane A., BOZKURT A., Cetin M.
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.21, no.2, pp.93-99, 2011 (Journal Indexed in SCI)
- XXV. **Functional Effects of Endothelial Nitric Oxide Synthase Genetic Polymorphisms on Haemorrhological Parameters in Healthy Human Individuals**
BABAĞLU M. Ö., Dikmenoglu N., Ileri-Gurel E., Serincec N., Zoto T., YAŞAR Ü., Kayaalp S. O., Bozkurt A.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.108, no.3, pp.171-176, 2011 (Journal Indexed in SCI)
- XXVI. **What is the role of drug metabolisms in treatment resistance?**
YAŞAR Ü., BABAĞLU M. Ö.
KLINIK PSIKOFARMAKOLOJİ BULTENİ-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, vol.19, 2009 (Journal Indexed in SCI)
- XXVII. **Disposition of a CYP2C9 phenotyping agent, losartan, is not influenced by the common 3435C > T variation of the drug transporter gene ABCB1 (MDR1)**
YAŞAR Ü., BABAĞLU M. Ö., Bozkurt A.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.103, no.2, pp.176-179, 2008 (Journal Indexed in SCI)
- XXVIII. **Pharmacotherapy resistance in patients undergoing resective epilepsy surgery due to hippocampal sclerosis is not associated with C3435T polymorphism in the ABCB1 (MDR1) gene**
Yasar U., Babaoglu M. O., Dericoglu N., Bal B., Bozkurt A., Saygi S.

FUNDAMENTAL & CLINICAL PHARMACOLOGY, vol.22, pp.51, 2008 (Journal Indexed in SCI)

- XXIX. **Multidrug resistance in patients undergoing resective epilepsy surgery is not associated with C3435T polymorphism in the ABCB1 (MDR1) gene**
DERİCİOĞLU N., BABAOĞLU M. Ö. , YAŞAR Ü., BAL I. B. , BOZKURT A., SAYGI S.
EPILEPSY RESEARCH, vol.80, no.1, pp.42-46, 2008 (Journal Indexed in SCI)
- XXX. **Molecular diagnosis and clinical characterization of pseudohypoparathyroidism type-Ib in a patient with mild Albright's hereditary osteodystrophy-like features, epileptic seizures, and defective renal handling of uric acid**
ÜNLÜTÜRK U., HARMANCI A., Babaoglu M., YAŞAR Ü., VARLI K., Bastepe M., BAYRAKTAR M.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, vol.336, no.1, pp.84-90, 2008 (Journal Indexed in SCI)
- XXXI. **Effect of raloxifene on cerebral vasospasm following experimental subarachnoid hemorrhage in rats**
Gulsen S., Inci S., Yuruk S., YAŞAR Ü., Ozgen T.
NEUROLOGIA MEDICO-CHIRURGICA, vol.47, no.12, pp.537-542, 2007 (Journal Indexed in SCI)
- XXXII. **Inhibitory effect of valproic acid on cytochrome p450 2C9 activity in epilepsy patients**
Gunes A., Bilir E., Zengil H., Babaoglu M. O. , Bozkurt A., Yasar U.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.100, no.6, pp.383-386, 2007 (Journal Indexed in SCI)
- XXXIII. **Differential alteration of drug-metabolizing enzyme activities after cyclophosphamide/adriamycin administration in breast cancer patients**
Elkiran T., Harputioglu H., Yasar U., Babaoglu M. O. , Dincel A. K. , Altundag K., Ozisik Y., Guler N., Bozkurt A.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, vol.29, no.1, pp.27-32, 2007 (Journal Indexed in SCI)
- XXXIV. **Capecitabine-induced severe hypertriglyceridemia: Report of two cases**
Kurt M., Babaoglu M., Yasar U., Shorbagi A., Guler N.
ANNALS OF PHARMACOTHERAPY, vol.40, no.2, pp.328-331, 2006 (Journal Indexed in SCI)
- XXXV. **Inhibitory effect of 5-fluorouracil on cytochrome P4502C9 activity in cancer patients**
Gunes A., Coskun U., Boruban C., Gunel N., Babaoglu M., Sencan O., Bozkurt A., Rane A., Hassan M., Zengil H., et al.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, vol.98, no.2, pp.197-200, 2006 (Journal Indexed in SCI)
- XXXVI. **Hepatotoxicity due to a possible interaction between cytosine arabinoside and dipyrindamole: a case report**
Babaoglu M., Karadag O., Saikawa Y., Altundag K., Elkiran T., Yasar U., Bozkurt A.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.60, no.6, pp.455-456, 2004 (Journal Indexed in SCI)
- XXXVII. **Functional impact of CYP2C*5, CYP2C9*6, CYP2C9*8, and CYP2C9*11 in vivo among black Africans**
Allabi A., Gala J., Horsmans Y., Babaoglu M., Bozkurt A., Heusterspreute M., Yasar U.
CLINICAL PHARMACOLOGY & THERAPEUTICS, vol.76, no.2, pp.113-118, 2004 (Journal Indexed in SCI)
- XXXVIII. **CYP2C9 genetic variants and losartan oxidation in a Turkish population**
Babaoglu M., Yasar U., Sandberg M., Eliasson E., Dahl M., Kayaalp S., Bozkurt A.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.60, no.5, pp.337-342, 2004 (Journal Indexed in SCI)
- XXXIX. **Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype**
Dericioglu N., BABAOĞLU M. Ö. , SAYGI S., BOZKURT A., YASAR U.
ANNALS OF PHARMACOTHERAPY, vol.38, no.5, pp.899, 2004 (Journal Indexed in SCI)
- XL. **5-fluorouracil-induced coronary spasm: May inhibition of hyperpolarization factors produced by CYP2C enzymes be the cause?**
Karadag O., Babaoglu M., Altundag K., Elkiran T., Yasar U., Bozkurt A.
ONCOLOGY, vol.66, no.6, pp.510-511, 2004 (Journal Indexed in SCI)
- XLI. **Analysis of CYP2C9*5 in Caucasian, Oriental and black-African populations**
Yasar U., Akillu E., Canaparo R., Sandberg M., Sayi J., Roh H., Wennerholm A.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, vol.58, no.8, pp.555-558, 2002 (Journal Indexed in SCI)
- XLII. **Subretinal fluid levels of topical, oral, and combined administered ciprofloxacin in humans**
Cekic O., Batman C., Yasar U., Basci N. E. , Zilelioglu O., Bozkurt A.
BRITISH JOURNAL OF OPHTHALMOLOGY, vol.84, no.9, pp.1061-1063, 2000 (Journal Indexed in SCI)

Articles Published in Other Journals

- I. **An overview of the significance of troponin in acute myocardial infarction**
ÜNAL Ş., ER ÖZTAŞ Y., YAŞAR Ü.
Acta Medica, vol.4, 2015 (Other Refereed National Journals)

Refereed Congress / Symposium Publications in Proceedings

- I. **İlaçlara Bağlı Dişeti Hipertrofisine İlaç Taşıyıcı Proteini MDR1 Genetik Polimorfizmlerinin Etkisi**
ÇAĞLAYAN F., ŞÜKÜROĞLU E., GÖKTAŞ M. T. , YAŞAR Ü., BABAOĞLU M. Ö. , ÇEVİK L., MÜDERRİSOĞLU A., atilla b., özgür k.
23. Ulusal Farmakoloji Kongresi, Turkey, 7 - 10 September 2015
- II. **Endotelial Nitrik Oksit Sentaz eNOS Genetik Polimorfizmlerinin İlaç Kullanımına Bağlı Dişeti Hipertrofisine Etkisi**
MÜDERRİSOĞLU A., ÇEVİK L., BABAOĞLU M. Ö. , YAŞAR Ü., bozkurt a., karaca ö., GÖKTAŞ M. T. , ŞÜKÜROĞLU E., ÇAĞLAYAN F.
23. Ulusal Farmakoloji Kongresi, Turkey, 7 - 10 September 2015
- III. **Evaluation of Graduate Students Scientific Development at the Hacettepe University Graduate School of Health Sciences**
ÖZTÜRK ÇOPUR E., TOZKOPARAN B., KARABULUT E., YAŞAR Ü., FADILLIOĞLU E.
10th ORPHEUS Conference Challenges in evaluation of research outcomes in PhD education, Sırbistan, Belgium, 16 - 18 April 2015
- IV. **Relationship between genetic polymorphisms of multidrug resistance gene MDR1 (ABCB1) and clearance of 99mTc-MIBI**
Kapulu-Akca C., Goktas M., Babaoglu M. O. , Altundag K., Yasar U., Celik I., Bozkurt A., Erbas B.
23rd Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Vienna, Austria, 9 - 13 October 2010, vol.37
- V. **Association of serotonin transporter gene SLC6A4 polymorphisms with alcohol dependence in a Turkish population**
KARACA Ö., BABAOĞLU M. Ö. , YAŞAR Ü., AYHAN Y., GÜREL Ş. C. , DİLBAZ H. N. , DEMİR B., ULUĞ B. D. , BOZKURT A.
9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics(ISSX), 4 - 08 September 2010
- VI. **What if a hypertensive patient taking losartan has genetic polymorphism of cyp2c9?**
Pepedil F., Goktas M., Tulumen E., Evranos B., Yasar U., Babaoglu M. O. , Cakir B., Guven G. S.
ESC Congress, Stockholm, Sweden, 28 August - 01 September 2010, vol.31, pp.692
- VII. **Association of serotonin transporter gene (SLC6A4) polymorphisms with alcohol dependence in a Turkish population**
KARACA O. R. , BABAOĞLU M. Ö. , YAŞAR Ü., AYHAN Y., GÜREL Ç. S. , DILBAZ N., DEMİR B., ULUG B., Bozkurt A.
9th International Meeting of the International-Society-for-the-Study-of-Xenobiotics(ISSX), İstanbul, Turkey, 4 - 08 September 2010, vol.42, pp.255-256
- VIII. **Türk Alkol Bağımlılarında Serotonin Promotr Bölge Polimorfizmleri**
GÜREL Ş. C. , AYHAN Y., BABAOĞLU M. Ö. , YAŞAR Ü., DEMİR B., ULUĞ B. D. , Bozkurt A., DİLBAZ H. N.
44. Ulusal Psikiyatri Kongresi, Turkey, 14 - 19 October 2008
- IX. **Association of the 3435C > T polymorphism of the drug transporter gene ABCB1 with colchicine response in patients with familial mediterranean fever**
Babaoglu M. O. , Yasar U., Tufan A., Akdogan A., Calguneri M., Kiraz S., Bozkurt A.
Experimental Biology 2007 Annual Meeting, Washington, Kiribati, 28 April - 02 May 2007, vol.21
- X. **Inhibitory effect of valproic acid on cytochrome P4502C9 activity in epilepsy patients**
Yasar U., Gunes A., Babaoglu M. O. , Bilir E., Zengil H., Bozkurt A.
Experimental Biology 2007 Annual Meeting, Washington, Kiribati, 28 April - 02 May 2007, vol.21
- XI. **Association of the cytochrome P450 1A2*1F polymorphism with clozapine response in schizophrenic**

patients

Yasar U, Babaoglu M. O. , Balibey H., Cetin M., Lundgren S., Rane A., Bozkurt A.

Experimental Biology 2007 Annual Meeting, Washington, Kiribati, 28 April - 02 May 2007, vol.21

- XII. **Disposition of a CYP2C9 phenotyping agent losartan is not influenced by the 3435C > T variation in the drug transporter gene ABCB1 in human**
Babaoglu M. O. , Yasar U, Bozkurt A.
Experimental Biology 2007 Annual Meeting, Washington, Kiribati, 28 April - 02 May 2007, vol.21
- XIII. **Differential alteration of drug metabolizing enzyme activities after cyclophosphamide/adriamycin administration in breast cancer patients**
Yasar U, Babaoglu M. O. , Elkiran T., Harputluoglu H., Dincel A., Altundag K., Guler N., Bozkurt A.
Experimental Biology 2007 Annual Meeting, Washington, Kiribati, 28 April - 02 May 2007, vol.21
- XIV. **Effect of atorvastatin on CYP2C9 metabolic activity in hypercholesterolemic patients**
Babaoglu M. O. , Yasar U, Yardimci Y., Kilicaslar A., Sain-Guven G., Bozkurt A.
Experimental Biology 2007 Annual Meeting, Washington, Kiribati, 28 April - 02 May 2007, vol.21
- XV. **Effect of the cardiopulmonary bypass procedure during cardiac surgery on CYP2C9 activity in human**
Babaoglu M. O. , Yasar U, Yorgancioglu C., Ozyuksel A., Akbulut B., Bozkurt A.
Experimental Biology 2007 Annual Meeting, Washington, Kiribati, 28 April - 02 May 2007, vol.21
- XVI. **Drug transporter gene MDR1 polymorphism C3435T may explain colchicine nonresponsiveness in familial Mediterranean fever**
Tufan A, Babaoglu M., Akdogan A., Yasar U, Calguneri M., Kalyoncu U., Karadag O., Ertenli A., Bozkurt A., Kiraz S.
Annual European Congress of Rheumatology (EULAR 2006), Amsterdam, Netherlands, 21 - 24 June 2006, vol.65, pp.100
- XVII. **Differential alteration of drug metabolizing enzyme activities in vivo after cyclophosphamide/doxorubicin administration in operable breast cancer patients.**
Elkiran E., Altundag K., Babaoglu M., Yasar U, Ozisik Y., Guler N., Dincel A., Bozkurt A.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XVIII. **Effects of CYP2C9*5,*6,*8 and *11 polymorphisms on losartan oxidation among black Africans**
Allabi A., Gala J., Horsmans Y., Babaoglu M., Bozkurt A., Heusterspreute M., Yasar U.
8th World Congress of Clinical Pharmacology and Therapeutics, Brisbane, Australia, 1 - 06 August 2004, vol.31
- XIX. **Tamoxifen inhibits cytochrome P4502C9 activity: A possible mechanism for tamoxifen-warfarin interaction.**
Boruban M., Babaoglu M., Sencan O., Bozkurt A., Yasar U.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

Supported Projects

YAŞAR Ü., Project Supported by Higher Education Institutions, Behçet Hastalarında P-Glikoprotein ve Sitokrom P450 2C (CYP2C9 ve CYP2C19) Genetik Polimorfizm ve Aktivitelerinin İncelenmesi, 2012 - 2018

Citations

Total Citations (WOS):495

h-index (WOS):12